» Articles » PMID: 33860059

A Role of Glucose Overload in Diabetic Cardiomyopathy in Nonhuman Primates

Overview
Journal J Diabetes Res
Publisher Wiley
Specialty Endocrinology
Date 2021 Apr 16
PMID 33860059
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes (T2D) plays a major role in the development of heart failure. Patients with T2D have an increased risk to develop HF than healthy subjects, and they always have very poor outcomes and survival rates. However, the underlying mechanisms for this are still unclear. To help develop new therapeutic interventions, well-characterized animal models for preclinical and translational investigations in T2D and HF are urgently needed. Although studies in rodents are more often used, the research findings in rodents have often failed to be translated into humans due to the significant metabolic differences between rodents and humans. Nonhuman primates (NHPs) serve as valuable translational models between basic studies in rodent models and clinical studies in humans. NHPs can recapitulate the natural progress of these diseases in humans and study the underlying mechanism due to their genetic similarity and comparable spontaneous T2D rates to humans. In this review, we discuss the importance of using NHPs models in understanding diabetic cardiomyopathy (DCM) in humans with aspects of correlations between hyperglycemia and cardiac dysfunction progression, glucose overload, and altered glucose metabolism promoting cardiac oxidative stress and mitochondria dysfunction, glucose, and its effect on cardiac resynchronization therapy with defibrillator (CRT-d), the currently available diabetic NHPs models and the limitations involved in the use of NHP models.

Citing Articles

Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors.

Al Thani N, Hasan M, Yalcin H J Cardiovasc Transl Res. 2023; 16(5):975-986.

PMID: 37052784 PMC: 10615955. DOI: 10.1007/s12265-023-10379-5.


Novel model predicts diastolic cardiac dysfunction in type 2 diabetes.

Hao M, Huang X, Liu X, Fang X, Li H, Lv L Ann Med. 2023; 55(1):766-777.

PMID: 36908240 PMC: 10798288. DOI: 10.1080/07853890.2023.2180154.


Signaling Pathways Related to Oxidative Stress in Diabetic Cardiomyopathy.

Peng M, Fu Y, Wu C, Zhang Y, Ren H, Zhou S Front Endocrinol (Lausanne). 2022; 13:907757.

PMID: 35784531 PMC: 9240190. DOI: 10.3389/fendo.2022.907757.


Research('s) Sweet Hearts: Experimental Biomedical Models of Diabetic Cardiomyopathy.

Richter C, Hinkel R Front Cardiovasc Med. 2021; 8:703355.

PMID: 34368257 PMC: 8342758. DOI: 10.3389/fcvm.2021.703355.

References
1.
Wende A, Abel E . Lipotoxicity in the heart. Biochim Biophys Acta. 2009; 1801(3):311-9. PMC: 2823976. DOI: 10.1016/j.bbalip.2009.09.023. View

2.
Wagner J, Carlson C, OBrien T, Anthony M, Bullock B, Cefalu W . Diabetes mellitus and islet amyloidosis in cynomolgus monkeys. Lab Anim Sci. 1996; 46(1):36-41. View

3.
Ma H, Li S, Xu P, Babcock S, Dolence E, Brownlee M . Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med. 2009; 13(8B):1751-1764. PMC: 2829341. DOI: 10.1111/j.1582-4934.2008.00547.x. View

4.
Habibi J, Aroor A, Sowers J, Jia G, Hayden M, Garro M . Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017; 16(1):9. PMC: 5237274. DOI: 10.1186/s12933-016-0489-z. View

5.
Zhang L, Liebelt J, Madan N, Shan J, Taub C . Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction. Am J Cardiol. 2017; 119(11):1815-1820. DOI: 10.1016/j.amjcard.2017.03.005. View